Monday, October 6, 2025

Latest

GameStop: Analyst Expectations For GME’s Fourth Quarter

GameStop (NYSE: GME) announced that they will be reporting their fourth quarter and year-end financials after hours on March 23rd. Analysts have a consensus $14.64 12-month price target on the company, via a total of seven analysts, with four analysts having a hold rating and three analysts having a sell rating on the company. The street high comes in at a $36 price target, and the lowest target comes from Credit Suisse with a $3.50 price target.

Six analysts have revenue estimates for the fourth quarter. The mean between all 16 is $2.2 billion; this number has been revised downwards from $2.4 billion at the start of the year. The highest analyst esimate is currently $2.36 billion, while the lowest comes from Credit Suisse with a $2 billion estimate.

For the full year, the average revenue estimate between six analysts is currently $5.18 billion. This number has been revised downwards from $5.38 billion at the start of the year. The highest analyst estimate is currently $5.33 billion, while the lowest comes from Credit Suisse with a $5 billion estimate.

Onto EBITDA estimates, there are currently five analysts who have fourth-quarter EBITDA estimates. The mean is currently $143.27 million, with this number having been revised down from $184.78 million at the start of the year. Street high is a $177.40 million EBITDA estimate and the lowest being from Credit Suisse with a $102.8 million estimate.

For the full year, the current EBITDA mean across only two analysts is -$71.56 million. This number has been revised down from -$25.78 million, where it sat at the start of the year.

Analysts estimate that quarterly earnings per share will come in at $1.47, with this number being revised down from $1.70 at the start of the year. Street high is $2.08 and the lowest estimate is $1.18 for the quarter.

For the full year, the current earnings per share estimate mean across only two analysts is -$3.27, with this number having been revised down from -$3.03 at the start of the year.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Fortune Bay: The Potential Billion Dollar Project

Japan Gold Enters New Chapter as Barrick Alliance Concludes – John Proust

Barrick Mining’s “Company Defining [Gold] Discovery”

Recommended

Nord Precious Metals Produces High Grade Silver Concentrate From Tailings

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Related News

Medipharm Labs: Canaccord Drops Target To Just $0.10

On May 16, Medipharm Labs (TSX: LABS) reported its first quarter financial results. The company...

Tuesday, May 24, 2022, 11:37:00 AM

Canaccord Lowers Curaleaf’s Price Target After Soft Q3 Results

On November 8th, Curaleaf Holdings (CSE: CURA) reported its third-quarter financial results. The firm reported...

Saturday, November 13, 2021, 10:15:00 AM

Cameco: Canaccord Refers To Firm As “Go-To” Name For Uranium Exposure

On February 9th, Cameco (TSX: CCO) reported its full-year 2021 financial results. The company reported...

Saturday, February 12, 2022, 02:03:00 PM

BMO Reiterates Ratings On Cineplex After Improved Sequential Revenues

On August 12, Cineplex Inc. (TSX: CGX) reported its second-quarter financial statements. The company reported...

Monday, August 16, 2021, 02:44:00 PM

Jushi: Canaccord Raises Estimates Following Nature’s Remedy Acquisition

On September 13th, Jushi Holdings (CSE: JUSH) announced that they completed their acquisition of Nature’s...

Wednesday, September 15, 2021, 10:58:00 AM